LAURUSLABS Q4 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,812 Cr
verified against source
Revenue YoY
23%
reported change
EBITDA
₹1,826 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Laurus Labs delivered a strong FY26 with revenue of ₹6,813 crore (+23% YoY) and EBITDA margin expansion of 670 bps to 26.8%, driven by a 38% surge in small molecule CDMO (₹1,896 crore) and 18% growth in affordable medicines (₹4,733 crore). PAT jumped 148% to ₹889 crore as gross margins improved to 60.4% on better mix and raw material softening. Management guided for continued CDMO growth, with capex of ₹3,000 crore over two years for capacity expansion (Unit 7, peptide, fermentation). However, geopolitical disruptions could pressure raw material availability and logistics, posing near-term headwinds for the generics business.
Colored figures show movement against the previous available record.
Guidance to track
- Increased from earlier ₹1,000 crore annually; 90% towards mid/large-scale manufacturing.
- Management reiterated target; ARV sales to remain constant in absolute terms.
- Confident in maintaining stable margins despite solvent price pressures.
- Greenfield project; additional blocks in FY28 with combined 2,000 m³ reactor volume.
Risks flagged
- Management noted increasing geopolitical tensions may pressure OTF performance in generics.
- Q4 FY26 saw some impact; management expects to weather via mix and utilization.
- Analyst raised concern; management stated three commercial APIs have long patent life and clear forecasts, but no granular disclosure.
- Management deferred specifics on OLED collaboration and crop science ramp-up, indicating multi-quarter uncertainty.
Key quotes
- We are a strategic partner for many big pharma right now. So we have a flow of RFP commercial early stage mid-stage late stage commercial.
- Most of the capex what we're doing is growth capex. We are not putting capex and hoping customer will come and give projects.
- We are very confident on maintaining or improving stable margin in FY27.
Research modules